{"id":"W4410804953","doi":"10.1200/jco.2025.43.16_suppl.tps9604","title":"TeLuRide-006: An adaptive phase 2/3 study of EIK1001, a Toll-like receptor 7/8 (TLR7/8) agonist, in combination with pembrolizumab in patients with advanced melanoma.","year":2025,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Health Sciences Centre; Sunnybrook Health Science Centre","funders":"","keywords":"Medicine; Pembrolizumab; Agonist; TLR7; TLR9; Toll-like receptor; Cancer research; Receptor; Toll-Like Receptor 9; Oncology; Internal medicine; Immunotherapy; Cancer; Gene; Innate immune system; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001494229,0.001701091,0.001505028,0.000579791,0.0003801537,0.0008188292,0.001044042,0.001523999,0.006838322],"category_scores_gemma":[0.0007151745,0.0006407309,0.001220317,0.0003803371,0.0009244803,0.001005432,0.0004007028,0.003565884,0.001259791],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007439389,"about_ca_system_score_gemma":0.0013248,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007622108,"about_ca_topic_score_gemma":0.001762832,"domain_scores_codex":[0.9996865,0.0001399916,0.00001354691,0.00005489972,0.00003200627,0.00007306359],"domain_scores_gemma":[0.9994847,0.00008802873,0.0001037503,0.00003983044,0.0000414023,0.0002423445],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.769438,0.1006434,0.00478732,0.001057037,0.001164054,0.0002169468,0.0002276195,0.001659139,0.03922622,0.0003415532,0.003711879,0.0775268],"study_design_scores_gemma":[0.6657907,0.3233043,0.005270995,0.00002701756,0.0003149642,0.0001626649,0.00004309257,0.0005054165,0.00262637,0.0001179579,0.001816475,0.00001998829],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9867518,0.002096362,0.000620483,0.000592994,0.0001730589,0.005275872,0.001611611,0.0001550471,0.002722731],"genre_scores_gemma":[0.982056,0.001821823,0.002166798,0.001637111,0.0002126847,0.005428798,0.002173372,0.00005432056,0.004449178],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006838322,"threshold_uncertainty_score":0.02287644,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04008054253250323,"score_gpt":0.4177264549160286,"score_spread":0.3776459123835254,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}